MicroStockProfit.com: BSMD's total worldwide revenues for first-quarter 2010 decline 2%

MicroStockProfit.com announces an investment report featuring BioSphere Medical Inc. (Nasdaq:BSMD). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/ads/BSMD

BioSphere Medical Inc. (BSMD) develops, markets and manufactures products for medical procedures, which uses embolotherapy. Embolotherapy is the minimally invasive, image-guided therapeutic introduction of various biocompatible substances into a patient's circulatory system to occlude a blood vessel, either to arrest or prevent hemorrhaging, or to devitalize or destroy the structure by occluding its blood supply. The technologies consist of bioengineered polymers, which are chemical compounds created through the application of medical science, engineering principles and manufacturing methods. As of December 31, 2009, the Company marketed and sold four microsphere products: EmboSphere Microspheres, EmboGold Microspheres, HepaSphere Microspheres and QuadraSphere Microspheres. 

Message Board Search for BSMD: http://www.boardcentral.com/boards/BSMD

In the report, the analyst notes:

"Total worldwide revenue for the first quarter of 2010 was $7.12 million, compared with $7.28 million in the first quarter of 2009, a decline of 2%. Total revenue in the first quarter of this year includes $0.08 million from Nippon Kayaku, the Company's distribution partner in Japan.  

"BSMD - the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy - recently reported that it has entered into an a definitive agreement and plan of merger with Merit Medical Systems, Inc. and Merit BioAcquisition Co., a wholly owned subsidiary of Merit Medical pursuant to which BSMD will merge with and into Merit BioAcquisition Co. in a cash transaction valued at approximately $96 million."